Later Onset Fabry Disease, Cardiac Damage Progress in Silence: Experience With a Highly Prevalent Mutation.

[1]  S. Chiou,et al.  Evaluation of Proinflammatory Prognostic Biomarkers for Fabry Cardiomyopathy With Enzyme Replacement Therapy. , 2016, The Canadian journal of cardiology.

[2]  R. Desnick,et al.  α-Galactosidase A knockout mice: progressive organ pathology resembles the type 2 later-onset phenotype of Fabry disease. , 2015, The American journal of pathology.

[3]  Wen-Chung Yu,et al.  When is the best time to start enzyme replacement therapy in patients with cardiac-type Fabry disease? Experience from Taiwan, an area highly prevalent in this cardiac phenotype , 2015 .

[4]  M. Beer,et al.  Relation of burden of myocardial fibrosis to malignant ventricular arrhythmias and outcomes in Fabry disease. , 2014, The American journal of cardiology.

[5]  Wen-Chung Yu,et al.  Endomyocardial biopsies in patients with left ventricular hypertrophy and a common Chinese later-onset fabry mutation (IVS4 + 919G > A) , 2014, Orphanet Journal of Rare Diseases.

[6]  F. Tsai,et al.  Detecting multiple lysosomal storage diseases by tandem mass spectrometry--a national newborn screening program in Taiwan. , 2014, Clinica chimica acta; international journal of clinical chemistry.

[7]  R. Desnick,et al.  Targeted sequencing of over 4000 hypertrophic cardiomyopathy (HCM) patients for mutations causing HCM and Fabry disease: HCM mutations frequent in patients with GLA later-onset mutations, polymorphisms, and variants , 2014 .

[8]  Richard B. Thompson,et al.  T1 Mapping With Cardiovascular MRI Is Highly Sensitive for Fabry Disease Independent of Hypertrophy and Sex , 2013, Circulation. Cardiovascular imaging.

[9]  M. Gelb,et al.  Identification of infants at risk for developing Fabry, Pompe, or mucopolysaccharidosis-I from newborn blood spots by tandem mass spectrometry. , 2013, The Journal of pediatrics.

[10]  K. Ihara,et al.  Newborn screening for Fabry disease in Japan: prevalence and genotypes of Fabry disease in a pilot study , 2013, Journal of Human Genetics.

[11]  C. A. Fossati,et al.  Fabry disease peripheral blood immune cells release inflammatory cytokines: role of globotriaosylceramide. , 2013, Molecular genetics and metabolism.

[12]  S. K. White,et al.  Identification and Assessment of Anderson-Fabry Disease by Cardiovascular Magnetic Resonance Noncontrast Myocardial T1 Mapping , 2013, Circulation. Cardiovascular imaging.

[13]  C. Vargas,et al.  Globotriaosylceramide is correlated with oxidative stress and inflammation in Fabry patients treated with enzyme replacement therapy. , 2012, Biochimica et biophysica acta.

[14]  Thomas P. Mechtler,et al.  Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria , 2012, The Lancet.

[15]  M. Beer,et al.  Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment. , 2011, JACC. Cardiovascular imaging.

[16]  Shing‐Jong Lin,et al.  High Incidence of the Cardiac Variant of Fabry Disease Revealed by Newborn Screening in the Taiwan Chinese Population , 2009, Circulation. Cardiovascular genetics.

[17]  M. Beer,et al.  Long-Term Effects of Enzyme Replacement Therapy on Fabry Cardiomyopathy Evidence for a Better Outcome With Early Treatment , 2009 .

[18]  A. Linhart,et al.  Onset and progression of the Anderson-Fabry disease related cardiomyopathy. , 2008, International journal of cardiology.

[19]  A. Cano,et al.  [Fabry disease in childhood]. , 2007, Presse medicale.

[20]  R. Desnick,et al.  High incidence of later-onset fabry disease revealed by newborn screening. , 2006, American journal of human genetics.

[21]  H. Ju,et al.  Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy. , 2006, The American journal of cardiology.

[22]  M. Burnier,et al.  Cardiac and Vascular Hypertrophy in Fabry Disease: Evidence for a New Mechanism Independent of Blood Pressure and Glycosphingolipid Deposition , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[23]  Richard B Devereux,et al.  Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardio , 2005, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[24]  Michael Jerosch-Herold,et al.  Utility of Cardiac Magnetic Resonance Imaging in the Diagnosis of Hypertrophic Cardiomyopathy , 2005, Circulation.

[25]  M. Drazner,et al.  Left Ventricular Hypertrophy Is More Prevalent in Blacks Than Whites in the General Population: The Dallas Heart Study , 2005, Hypertension.

[26]  C. Eng,et al.  Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype. , 2003, Kidney international.

[27]  S. Packman,et al.  Fabry Disease, an Under-Recognized Multisystemic Disorder: Expert Recommendations for Diagnosis, Management, and Enzyme Replacement Therapy , 2003, Annals of Internal Medicine.

[28]  R. Desnick,et al.  Alternative splicing in the alpha-galactosidase A gene: increased exon inclusion results in the Fabry cardiac phenotype. , 2002, American journal of human genetics.

[29]  H. Sakuraba,et al.  An atypical variant of Fabry's disease in men with left ventricular hypertrophy. , 1995, The New England journal of medicine.

[30]  S. Daniels,et al.  Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. , 1992, Journal of the American College of Cardiology.

[31]  C. Eng,et al.  An atypical variant of Fabry's disease with manifestations confined to the myocardium. , 1991, The New England journal of medicine.

[32]  Carlene Campbell,et al.  Lysosomal storage disorder screening implementation: findings from the first six months of full population pilot testing in Missouri. , 2015, The Journal of pediatrics.

[33]  J. Stockman.  Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria , 2013 .

[34]  A. Rolfs,et al.  Newborn screening for lysosomal storage disorders in hungary. , 2012, JIMD reports.

[35]  L. Mazzolai,et al.  Evidence for a role of sphingosine-1 phosphate in cardiovascular remodelling in Fabry disease. , 2010, European heart journal.

[36]  寺口 博幸.  Terminal stage cardiac findings in patients with cardiac Fabry disease : an electrocardiographic, echocardiographic, and autopsy study , 2008 .

[37]  Peter Bross,et al.  The Metabolic and Molecular Basis of Inherited Disease: Protein Folding and Misfolding: the Role of Cellular Protein Quality Control Systems in Inherited Disorders , 2005 .

[38]  R. Desnick,et al.  Fabry disease: renal involvement limited to podocyte pathology and proteinuria in a septuagenarian cardiac variant. Pathologic and therapeutic implications. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[39]  R. Desnick.  α-Galactosidase A deficiency. Fabry disease , 2001 .